Indeed, for patients with a baseline PSA level between 8 and 50 ng/mL, the risk of death from PCa was approximately 7.5 times higher in patients with a PSADT ≤12 months compared to patients with a PSADT of ≥12 months [37]. Here, KLK3 is linked to posterior cortical atrophy.